DAS181 for STOP COVID-19

NCT ID: NCT04354389

Last Updated: 2020-08-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2/PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-25
• Study Completion Date: 2020-11-30

Brief Summary

It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.

Detailed Description

The first stage is randomized, double-blind study to confirm the optimal dose of the study. Twenty-two (n=22) subjects with COVID-19 and clinically significant impairment of respiratory function will be enrolled to evaluate the two dosing regimens (4.5mg-q.d or 4.5mg-b.i.d) of DAS181. At the end of Stage 1, the Sponsor will evaluate the dose regimen based on the safety and efficacy assessments of the data. An optimal dose will be selected to proceed to Stage 2.

The second stage is a randomized, placebo-controlled and double-blind study to expand enrollment with an additional eighty-two (n=82) subjects to provide adequate power to potentially demonstrate statistically significant therapeutic efficacy.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

DAS181 b.i.d.+ standard local care for COVID-19

4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19

Group Type: EXPERIMENTAL

DAS181

Intervention Type: DRUG

4.5 mg q.d.

Placebo+ standard local care for COVID-19

nebulized inhalation for 10 consecutive days + standard local care for COVID-19

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

q.d. or b.i.d.

DAS181 q.d.+ standard local care for COVID-19

4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19

Group Type: EXPERIMENTAL

DAS181

Intervention Type: DRUG

4.5 mg b.i.d

Interventions

DAS181

4.5 mg b.i.d

Intervention Type: DRUG

Placebo

q.d. or b.i.d.

Intervention Type: DRUG

DAS181

4.5 mg q.d.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Be ≥18 years of age

2. Provide adequate medical history to permit accurate stratification by health status

3. Prior to SARS CoV 2 infection, has no chronic or recurring requirement for supplemental oxygen

4. Have lower respiratory tract infection (LRTI) confirmed by imaging

5. Has laboratory-confirmation of the presence of SARS-CoV-2 in the respiratory tract

6. At the time of randomization, requires supplemental oxygen ≥2 LPM for treatment of hypoxia or pulmonary stress as evidenced by at least one of the following:

1. Respiratory rate ≥ 30 breaths/min

2. SpO2 ≤93% at rest

3. PaO2/FiO2≤300 mmHg

4. Showing the progression of lung lesions within 24 to 48h by >50%

7. If female, subject must meet one of the following conditions:

1. Not be of childbearing potential or

2. Be of childbearing potential and have a negative urine/serum pregnancy test and agrees to practice an acceptable method of contraception

8. Non-vasectomized males are required to practice effective birth control methods

9. Capable of understanding and complying with procedures as outlined in the protocol

10. Provides signed informed consent prior to the initiation of any screening or study-specific procedures

Exclusion Criteria

1. At the time of randomization, classified as critical (life-threatening) disease

2. Subjects currently receiving any other investigational drug, as part of a clinical trial or under emergency approval for SARS-CoV-2

3. Subjects who are known asthmatic patients or HIV-positive

4. Subjects who are currently receiving inhaled biologics or anti-viral agents

5. Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent viral, bacterial, or fungal infection with vital organ failure or required vasopressors to maintain blood pressure

6. Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP) ≥3x ULN and Total Bilirubin (TBILI) ≥2xULN

7. Female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug.

8. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance.

9. Subjects with known hypersensitivity to DAS181 and/or any of its components.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ansun Biopharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jennifer Ho, MD, PhD

Role: STUDY_DIRECTOR

Ansun Biopharma, Inc.

Locations

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

Milan, , Italy

A.O.U Policlinico Di Modena

Modena, , Italy

Countries

Italy

Other Identifiers

2020-003192-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DAS181-2-08

Identifier Type: -

Identifier Source: org_study_id